Clinical trial
A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
NCT03514407 · Incyte Corporation, Industry · Terminated
Key facts
| NCT number | NCT03514407 |
|---|---|
| Title | A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma |
| Official title | An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma |
| Lead sponsor | Incyte Corporation, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Relapsed Ewing Sarcoma |
| Intervention type | Drug |
| Interventions | INCB059872 |
| Enrollment | 25 |
| Start date | Jun 27, 2018 |
| Primary completion | Jun 25, 2020 |
| Completion | Jun 25, 2020 |
| First posted | May 2, 2018 |
| Last update posted | Oct 21, 2025 |
| Countries | Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: